Compare ONTO & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTO | AXSM |
|---|---|---|
| Founded | 1940 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.6B |
| IPO Year | 1995 | 2015 |
| Metric | ONTO | AXSM |
|---|---|---|
| Price | $289.72 | $183.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $290.63 | $211.12 |
| AVG Volume (30 Days) | ★ 729.3K | 503.9K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 2.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.63 | $57.24 |
| Revenue Next Year | $16.26 | $55.88 |
| P/E Ratio | $106.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.40 | $96.09 |
| 52 Week High | $301.00 | $191.50 |
| Indicator | ONTO | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 70.96 | 60.51 |
| Support Level | $122.05 | $178.00 |
| Resistance Level | N/A | $184.40 |
| Average True Range (ATR) | 11.84 | 5.55 |
| MACD | 5.06 | 0.93 |
| Stochastic Oscillator | 88.38 | 72.42 |
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.